Michel Reich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michel Reich has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Nicolas Penel
Department of Medical Oncology Centre Oscar Lambret Lille France
4 shared publications - Pascal Antoine
Univ. Lille, CNRS, UMR 9193 - SCALab - Sciences Cognitives et Sciences Affectives, Univ. Lille, Lille, France
4 shared publications - Véronique Christophe
Département de Sciences Humaines et Sociales, Centre Léon Bérard (CLB), Lyon, France
4 shared publications - Charles Fournier
Centre Oscar-Lambret, 3, rue Combemale, 59020 Lille Cedex, France
2 shared publications Claude Adenis
Centre Oscar Lambret, France
2 shared publications- Emilie Le Rhun
Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich
2 shared publications
Latest Publications
- Open Access
- 1 June 2021
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 19 (3) , f1-f4
PAX volume 19 issue 3 Cover and Front matter
- 1 June 2021
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 19 (3) , f1-f4
Open AccessPAX volume 19 issue 3 Cover and Front matter
- 1 December 2019
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 13 (3-4) , 156-163
Stress et cancer : mythes et réalités
Les théories profanes émises par les patients et certains ouvrages destinés au grand public alimentent l’idée que le stress psychologique peut influencer le risque de survenue de cancer. Les études consultées sur cette question semblent donner des résultats contradictoires. D’un côté, ces théories peuvent sembler étayées par les résultats d’études expérimentales portant sur les corrélats physiologiques du stress sur des voies neuro-immunoendocrinologiques (perturbations immunitaires, altération de l’axe hypothalamohypophyso- surrénalien), métaboliques et cellulaires (stress oxydatif, dégénérescence cellulaire) pouvant être impliquées dans la tumorigenèse. De l’autre, les études épidémiologiques prospectives fondées sur une méthodologie robuste ne trouvent généralement pas d’association entre exposition au stress et développement ultérieur d’un cancer. Par ailleurs, les méta-analyses suggèrent l’existence de biais de publication pouvant surestimer le poids des études « positives ». Quand bien même une association est retrouvée, le caractère observationnel des études épidémiologiques et donc la possibilité de facteurs de confusion empêchent d’établir un lien de causalité entre l’exposition au stress et un risque majoré de cancer. En ce qui concerne les mécanismes d’une éventuelle relation causale directe, il faut souligner la difficulté d’extrapoler à l’être humain des résultats obtenus chez d’autres animaux, et s’assurer de bien prendre en compte la présence de facteurs comportementaux confondants ou médiateurs comme une mauvaise hygiène de vie alimentaire, la consommation de tabac et d’alcool, les expositions professionnelles, etc. Selon les recommandations du National Cancer Institute (NCI, 2012), les connaissances actuellement disponibles ne permettent pas d’établir un lien de causalité entre stress et augmentation du risque de cancer. Si le professionnel de soin psychique ne doit donc pas cautionner ce lien hypothétique au risque de culpabiliser le patient, il gardera à l’esprit, d’une part, que le cancer peut en revanche générer un stress bien réel au quotidien chez les patients atteints par cette maladie et, d’autre part, que ces théories « profanes » peuvent parfois témoigner d’un mécanisme de défense contre ce stress.
- 1 December 2019
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 13 (3-4) , 156-163
Stress et cancer : mythes et réalités
Les théories profanes émises par les patients et certains ouvrages destinés au grand public alimentent l’idée que le stress psychologique peut influencer le risque de survenue de cancer. Les études consultées sur cette question semblent donner des résultats contradictoires. D’un côté, ces théories peuvent sembler étayées par les résultats d’études expérimentales portant sur les corrélats physiologiques du stress sur des voies neuro-immunoendocrinologiques (perturbations immunitaires, altération de l’axe hypothalamohypophyso- surrénalien), métaboliques et cellulaires (stress oxydatif, dégénérescence cellulaire) pouvant être impliquées dans la tumorigenèse. De l’autre, les études épidémiologiques prospectives fondées sur une méthodologie robuste ne trouvent généralement pas d’association entre exposition au stress et développement ultérieur d’un cancer. Par ailleurs, les méta-analyses suggèrent l’existence de biais de publication pouvant surestimer le poids des études « positives ». Quand bien même une association est retrouvée, le caractère observationnel des études épidémiologiques et donc la possibilité de facteurs de confusion empêchent d’établir un lien de causalité entre l’exposition au stress et un risque majoré de cancer. En ce qui concerne les mécanismes d’une éventuelle relation causale directe, il faut souligner la difficulté d’extrapoler à l’être humain des résultats obtenus chez d’autres animaux, et s’assurer de bien prendre en compte la présence de facteurs comportementaux confondants ou médiateurs comme une mauvaise hygiène de vie alimentaire, la consommation de tabac et d’alcool, les expositions professionnelles, etc. Selon les recommandations du National Cancer Institute (NCI, 2012), les connaissances actuellement disponibles ne permettent pas d’établir un lien de causalité entre stress et augmentation du risque de cancer. Si le professionnel de soin psychique ne doit donc pas cautionner ce lien hypothétique au risque de culpabiliser le patient, il gardera à l’esprit, d’une part, que le cancer peut en revanche générer un stress bien réel au quotidien chez les patients atteints par cette maladie et, d’autre part, que ces théories « profanes » peuvent parfois témoigner d’un mécanisme de défense contre ce stress.
- 1 December 2019
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 13 (3-4) , 150-155
Stress, Inflammation and Cancer Prognosis: New Evidence-Based Effective Treatments
This article introduces the general model of stress, coping and adaptation applied to cancer, and biological mechanisms mediating psychological factors and cancer prognosis. The role of the vagus nerve as a possible bridge and therapeutic target in psycho-oncology is reviewed. Finally, the effects of brief psychological interventions (e.g., stress management) on cancer prognosis are presented. Psycho-oncology education and practice need to shift to a more evidence-based proactive approach, to help cancer patients adapt and possibly improve their quality and quantity of life.
- 1 December 2019
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 13 (3-4) , 150-155
Stress, Inflammation and Cancer Prognosis: New Evidence-Based Effective Treatments
This article introduces the general model of stress, coping and adaptation applied to cancer, and biological mechanisms mediating psychological factors and cancer prognosis. The role of the vagus nerve as a possible bridge and therapeutic target in psycho-oncology is reviewed. Finally, the effects of brief psychological interventions (e.g., stress management) on cancer prognosis are presented. Psycho-oncology education and practice need to shift to a more evidence-based proactive approach, to help cancer patients adapt and possibly improve their quality and quantity of life.
- 25 September 2019
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 18 (4) , 486-494
Refractory psycho-existential distress and continuous deep sedation until death in palliative care: The French perspective
Objective: Since February 2016, French Claeys-Leonetti law has recognized patients' right to confront incurable diseases with short-term prognosis and refractory physical or psychological or existential symptoms by requesting continuous deep sedation until death (CDSUD). Determining when psychological or existential distress is refractory and unbearable remains complex and controversial.This review provides a comprehensive thought on CDSUD for advanced incurable patients with refractory psychological and/or existential distress in palliative care settings. It offers guidance on psychiatric or psychological diagnosis for explaining patients' requests for CDSUD.Method: A narrative literature review (2000–2019) was conducted on the MedLine search about the use of palliative sedation in cases of refractory psychological and/or existential distress.Results: (1) Definitions of “refractory symptom,” “refractory psychological distress,” and “refractory existential distress” are inconsistent; (2) alternative diagnoses might obscure or be obscured by psycho-existential distress; and (3) criteria on meanings, reasons for requests, decision-making processes, and functions are evolving in practice.Significance of results: Before implementing CDSUD, palliative healthcare professionals should seek input from psycho-oncologists in palliative care. Mental health professionals should analyze and assess the reasons for psychological and/or existential distress, consider the intentionality processes of requests, and explore alternative diagnoses, such as depressive or adjustment disorders, demoralization syndrome, desire to hasten death, and desire for euthanasia. Therapeutic responses (e.g., pharmacological and psychotherapeutic) should be implemented before deciding that psycho-existential distress is refractory.
- 25 September 2019
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 18 (4) , 486-494
Refractory psycho-existential distress and continuous deep sedation until death in palliative care: The French perspective
Objective: Since February 2016, French Claeys-Leonetti law has recognized patients' right to confront incurable diseases with short-term prognosis and refractory physical or psychological or existential symptoms by requesting continuous deep sedation until death (CDSUD). Determining when psychological or existential distress is refractory and unbearable remains complex and controversial.This review provides a comprehensive thought on CDSUD for advanced incurable patients with refractory psychological and/or existential distress in palliative care settings. It offers guidance on psychiatric or psychological diagnosis for explaining patients' requests for CDSUD.Method: A narrative literature review (2000–2019) was conducted on the MedLine search about the use of palliative sedation in cases of refractory psychological and/or existential distress.Results: (1) Definitions of “refractory symptom,” “refractory psychological distress,” and “refractory existential distress” are inconsistent; (2) alternative diagnoses might obscure or be obscured by psycho-existential distress; and (3) criteria on meanings, reasons for requests, decision-making processes, and functions are evolving in practice.Significance of results: Before implementing CDSUD, palliative healthcare professionals should seek input from psycho-oncologists in palliative care. Mental health professionals should analyze and assess the reasons for psychological and/or existential distress, consider the intentionality processes of requests, and explore alternative diagnoses, such as depressive or adjustment disorders, demoralization syndrome, desire to hasten death, and desire for euthanasia. Therapeutic responses (e.g., pharmacological and psychotherapeutic) should be implemented before deciding that psycho-existential distress is refractory.
- 27 June 2018
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 17 (1) , 119-121
“Impossible” patients in oncology: Two unusual cases
Cancer patients can present with impossible behavior, which can jeopardize their treatment and challenge healthcare professionals’ teamwork. Report of two unusual psychiatric cases, including Munchausen and Peter Pan syndromes, which occurred in a comprehensive cancer center. Guidelines in medical and surgical wards are suggested to address such situations regarding oncologic compliance. Multidisciplinary collaboration between medical and surgical teams and the psycho-oncologic department is highly recommended.
- 27 June 2018
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 17 (1) , 119-121
“Impossible” patients in oncology: Two unusual cases
Cancer patients can present with impossible behavior, which can jeopardize their treatment and challenge healthcare professionals’ teamwork. Report of two unusual psychiatric cases, including Munchausen and Peter Pan syndromes, which occurred in a comprehensive cancer center. Guidelines in medical and surgical wards are suggested to address such situations regarding oncologic compliance. Multidisciplinary collaboration between medical and surgical teams and the psycho-oncologic department is highly recommended.
- 1 June 2018
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 12 (2) , 83-85
Maladie mentale et cancer
- 1 June 2018
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 12 (2) , 83-85
Maladie mentale et cancer
- 1 June 2018
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 12 (2) , 114-130
Place des psychotropes en oncologie
Les psychotropes font partie des thérapeutiques pharmacologiques classiques des troubles mentaux. Ils comprennent les anxiolytiques, les antidépresseurs, les antipsychotiques ou neuroleptiques, les thymorégulateurs, les hypnotiques, les psychostimulants et les anticonvulsivants. En oncologie, ils comportent d’autres indications potentielles telles que les bouffées vasomotrices, les douleurs neuropathiques, les nausées et vomissements réfractaires aux antiémétiques usuels, le hoquet, le prurit, et les états de fatigue et la cachexie liés à des cancers en phase avancée. Certaines particularités propres à leur utilisation en cancérologie et leurs modalités de prescription seront détaillées dans cet article. Psychotropic drugs are part of the usual pharmacological therapeutics for psychiatric disorders. They include anxiolytics, antidepressants, antipsychotics or neuroleptics, mood stabilizers, hypnotics, psychostimulants, and anticonvulsants. In oncology, they have other potential indications such as hot flushes, neuropathic pain, nausea and vomiting refractory to usual antiemetics, hiccups, pruritus and advanced cancer related cachexia or fatigue. Some specificities due to their use in oncology and modalities of their prescription will be detailed in this article.
- 1 June 2018
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 12 (2) , 114-130
Place des psychotropes en oncologie
Les psychotropes font partie des thérapeutiques pharmacologiques classiques des troubles mentaux. Ils comprennent les anxiolytiques, les antidépresseurs, les antipsychotiques ou neuroleptiques, les thymorégulateurs, les hypnotiques, les psychostimulants et les anticonvulsivants. En oncologie, ils comportent d’autres indications potentielles telles que les bouffées vasomotrices, les douleurs neuropathiques, les nausées et vomissements réfractaires aux antiémétiques usuels, le hoquet, le prurit, et les états de fatigue et la cachexie liés à des cancers en phase avancée. Certaines particularités propres à leur utilisation en cancérologie et leurs modalités de prescription seront détaillées dans cet article. Psychotropic drugs are part of the usual pharmacological therapeutics for psychiatric disorders. They include anxiolytics, antidepressants, antipsychotics or neuroleptics, mood stabilizers, hypnotics, psychostimulants, and anticonvulsants. In oncology, they have other potential indications such as hot flushes, neuropathic pain, nausea and vomiting refractory to usual antiemetics, hiccups, pruritus and advanced cancer related cachexia or fatigue. Some specificities due to their use in oncology and modalities of their prescription will be detailed in this article.
- 1 March 2018
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 12 (1) , 38-45
Parents atteints de cancer : comment en parler aux enfants ?
Quand un parent est atteint de cancer, la dynamique familiale est mise à l’épreuve, entraînant des répercussions à tous les niveaux, tant pour les parents que pour leurs enfants. Pourtant, il arrive encore régulièrement que peu de paroles soient échangées avec les enfants sur la maladie et ses conséquences. Certains professionnels se trouvent en difficulté pour accompagner le parent malade au sujet de ce qu’il doit transmettre aux enfants : qu’en dire, comment dire ?… Cet article s’appuie sur le référentiel « Parents atteints de cancer : comment en parler aux enfants ? ». Il vise à aider les professionnels à aborder ce sujet avec les patients pour encourager le dialogue dans la famille autour de la maladie et favoriser l’accès au soutien psychologique familial. L’objectif est de prévenir le risque de troubles psychopathologiques chez l’enfant. When a parent is diagnosed with cancer, the family dynamic is tested, entailing a range of repercussions for both parents and their children. However, there is still often very little discussion and words exchanged with children about the disease and its impacts. Some professionals may find difficulty in assisting the sick parent about giving relevant information: what to say, how to say… This article relies on the framework, “Parents with cancer: how to talk to children about it?” It aims to help the professionals to address this matter with patients, in order to foster meaningful dialogue and facilitate access to family psychological support. The aim is to prevent the risk of psychopathological disorders in the child.
- 1 March 2018
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 12 (1) , 38-45
Parents atteints de cancer : comment en parler aux enfants ?
Quand un parent est atteint de cancer, la dynamique familiale est mise à l’épreuve, entraînant des répercussions à tous les niveaux, tant pour les parents que pour leurs enfants. Pourtant, il arrive encore régulièrement que peu de paroles soient échangées avec les enfants sur la maladie et ses conséquences. Certains professionnels se trouvent en difficulté pour accompagner le parent malade au sujet de ce qu’il doit transmettre aux enfants : qu’en dire, comment dire ?… Cet article s’appuie sur le référentiel « Parents atteints de cancer : comment en parler aux enfants ? ». Il vise à aider les professionnels à aborder ce sujet avec les patients pour encourager le dialogue dans la famille autour de la maladie et favoriser l’accès au soutien psychologique familial. L’objectif est de prévenir le risque de troubles psychopathologiques chez l’enfant. When a parent is diagnosed with cancer, the family dynamic is tested, entailing a range of repercussions for both parents and their children. However, there is still often very little discussion and words exchanged with children about the disease and its impacts. Some professionals may find difficulty in assisting the sick parent about giving relevant information: what to say, how to say… This article relies on the framework, “Parents with cancer: how to talk to children about it?” It aims to help the professionals to address this matter with patients, in order to foster meaningful dialogue and facilitate access to family psychological support. The aim is to prevent the risk of psychopathological disorders in the child.
- 1 May 2017
- Published by Elsevier in Bulletin du Cancer
- Vol. 104 (5) , 442-451
Les troubles bipolaires en oncologie : caractéristiques et prise en charge
- 1 May 2017
- Published by Elsevier in Bulletin du Cancer
- Vol. 104 (5) , 442-451
Les troubles bipolaires en oncologie : caractéristiques et prise en charge
- 1 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (10) , 1848-1854
Best practice guidelines in the psychosocial management of HPV-related head and neck cancer: recommendations from the European Head and Neck Cancer Society's Make Sense Campaign
Over the past three decades, oral human papillomavirus (HPV) has been associated with an increase in the incidence of oropharyngeal squamous cell carcinoma (OPSCC) in several countries. Specialist oncologists in head and neck cancer are observing a wider range of demographics, sexual behaviours and survival outcomes with their patients. Additionally, there are fewer smokers, consumers of alcohol, or people of lower socioeconomic status than in previous decades. In order to support patients, the European Head and Neck Society's Make Sense Campaign aims to promote best practice in the management of head and neck cancer through the delivery of counselling, psychological assessment, support with the patient experience following HPV-related cancer diagnosis, sexual impact (in terms of communication, behaviour and prevention), facilitating access to educational resources about HPV in head and neck squamous cell carcinoma and OPSCC, and early referral if necessary. New concerns about psychosocial distress and unmet psychosocial needs following diagnosis, therefore, exist throughout the disease and treatment periods. Oncologists treating patients with HPV-related head and neck cancer must integrate new parameters focused on infection risk transmission and sexual topics. The development and dissemination of best practice guidelines through The European Head and Neck Cancer Society Make Sense Campaign will help healthcare professionals (HCPs) to be more confident and resourceful in supporting patients with HPV-related head and neck cancer.
- 1 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (10) , 1848-1854
Best practice guidelines in the psychosocial management of HPV-related head and neck cancer: recommendations from the European Head and Neck Cancer Society's Make Sense Campaign
Over the past three decades, oral human papillomavirus (HPV) has been associated with an increase in the incidence of oropharyngeal squamous cell carcinoma (OPSCC) in several countries. Specialist oncologists in head and neck cancer are observing a wider range of demographics, sexual behaviours and survival outcomes with their patients. Additionally, there are fewer smokers, consumers of alcohol, or people of lower socioeconomic status than in previous decades. In order to support patients, the European Head and Neck Society's Make Sense Campaign aims to promote best practice in the management of head and neck cancer through the delivery of counselling, psychological assessment, support with the patient experience following HPV-related cancer diagnosis, sexual impact (in terms of communication, behaviour and prevention), facilitating access to educational resources about HPV in head and neck squamous cell carcinoma and OPSCC, and early referral if necessary. New concerns about psychosocial distress and unmet psychosocial needs following diagnosis, therefore, exist throughout the disease and treatment periods. Oncologists treating patients with HPV-related head and neck cancer must integrate new parameters focused on infection risk transmission and sexual topics. The development and dissemination of best practice guidelines through The European Head and Neck Cancer Society Make Sense Campaign will help healthcare professionals (HCPs) to be more confident and resourceful in supporting patients with HPV-related head and neck cancer.